Last updated: 11/04/2018 06:04:09

A study to investigate the effects of GW876008 on brain activation during emotional processing in healthy subjects.

GSK study ID
CRH104150
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A randomized, placebo-controlled, double-dummy, four-way crossover design study to investigate the changes of fMRI BOLD activation induced by emotional activation paradigms following single doses of GW876008 and lorazepam (comparator) in healthy subjects.
Trial description: Data suggests that imaging activity of the brain can measure the effects of anti-anxiety drugs. This study will investigate the effect of GW876008 on areas of the brain involved with thinking and emotion
Primary purpose:
Diagnostic
Trial design:
Crossover Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:

GW876008 blood levels

Timeframe: pre-dose & post-dose, sessions 1-4

clinical rating scales change after dosing: questionnaires collected

Timeframe: pre-dose & up to 6-8 hours post-dose.

Interventions:
Drug: placebo
Drug: lorazepam
Drug: GW876008
Enrollment:
26
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Healthy Subjects
Product
emicerfont, lorazepam
Collaborators
Not applicable
Study date(s)
March 2007 to December 2007
Type
Interventional
Phase
1

Participation criteria

Sex
Female & Male
Age
18 - 50 Years
Accepts healthy volunteers
Yes
  • Healthy males or females aged 18-50 years, inclusive.
  • STAI-trait score = or > 40.
  • As a result of any of the medical interview, physical examination, evaluation of mental state and psychiatric history or screening investigations the physician responsible considers the subject unfit for the study.
  • Any history of suicidal attempts or behaviour.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
La Jolla, California, United States, 92093
Status
Study Complete

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2007-19-12

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website